In addition, two separate combinations were approved for two gynecological cancers: the microsatellite stable endometrial (Makker et al., 2019; Marth et al., 2022) and PD-L1 positive cervical cancers; these cancers respond well to the combination of PD-1 and VEGF pathway inhibition in combination with chemotherapy (Rubinstein & Makker, 2020). The gene discussed is VEGFA; the disease is cancer.